Poster

Cardiovascular (CV) Safety and Pharmacokinetics (PK) of Serdexmethylphenidate (SDX), a Prodrug of d-Methylphenidate (d-MPH) Compared to Ritalin and Ritalin LA in a Single-Dose Crossover Study in Healthy Volunteers

The presented study evaluated the CV safety and PK after SDX, a prodrug of d-MPH, relative to Ritalin IR and Ritalin LA. At an SDX dose (200 mg) of 2.5x the molar-equivalent Ritalin doses...

Rene Braeckman , PhD;

10/26/2023

Cardiovascular Burden of Patients Diagnosed With Idiopathic Hypersomnia: Real-World Idiopathic Hypersomnia Total Health Model (CV-RHYTHM)

This study compared the odds of cardiovascular (CV) conditions in patients with idiopathic hypersomnia (IH) versus matched non-IH controls using Merative™ MarketScan® administrative claim...

Jed Black , MD;

10/26/2023

Cariprazine as an Adjunctive Treatment for Major Depressive Disorder: Assessment of Benefit and Risk Using Number Needed to Treat and Number Needed to Harm

The benefit-risk profile of cariprazine is favorable for major depressive disorder adjunctive treatment.

Majid Kerolous , PharmD, MPH;

10/26/2023

Categorial Response Rates, Time Course of Response, and Symptom Domains of Response With KarXT (Xanomeline-Trospium) in the Phase 3 EMERGENT-2 Study

KarXT, a combination of xanomeline (dual M1/M4 muscarinic receptor agonist) and trospium (peripherally restricted muscarinic receptor antagonist), showed promising results in the EMERGENT...

Inder Kaul , MD;

10/26/2023

Centanafadine Sustained Release in the Treatment of Adult Attention-Deficit/Hyperactivity Disorder: Secondary Outcomes From a Phase 2a Study

Centanafadine (CTN) is a norepinephrine/dopamine/serotonin reuptake inhibitor being investigated for the treatment of attention-deficit/hyperactivity disorder (ADHD). Secondary efficacy o...

Jessica McDonough , MD;

10/26/2023

Changes in Metabolic Parameters Associated With Lumateperone in Late-Phase Clinical Trials for the Treatment of Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder

This analysis of 2 pooled, 6-week, placebo-controlled monotherapy studies; a 6-month open-label extension (OLE) monotherapy study; and a 6-week, placebo-controlled adjunctive study evalua...

Jazmin Acosta , PhD;

10/26/2023

Behavioral-, Neurologic-, Metabolic-, Endocrine-, and Cardiovascular-Related Adverse Events and Assessments in Patients With Schizophrenia Treated With TV-46000

TV-46000 is an FDA-approved long-acting subcutaneous antipsychotic (LASCA) formulation of risperidone that was shown to reduce time to impending relapse in patients with schizophrenia. Th...

Kelli R. Franzenburg , PhD;

10/26/2023

Best Practices for Mental Health Treatment Teams From the Perspective of Certified Peer Support Specialists (CPSS): Results of a CPSS Roundtable

Certified Peer Support Specialists (CPSS) are people with lived experience who serve on treatment teams to help guide peers in their recovery process. A CPSS roundtable was convened to as...

LaGenia Bailey , PharmD, BCPP;

10/26/2023

Budget Impact of Aripiprazole Once Every Two Months Long-Acting Injectable for Adult Patients with Bipolar-I Disorder in the US

In this study, a cost-offset analysis was conducted to evaluate the budget impact of introducing a new 2-monthly injectable formulation of aripiprazole in commercial health plans. In a hy...

Vakaramoko Diaby ;

10/26/2023

Budget Impact of Aripiprazole Once Every Two Months Long-Acting Injectable for Adult Patients with Schizophrenia in the US

A cost-offset analysis was conducted to evaluate the budget impact of introducing a new 2-monthly injectable formulation of aripiprazole in commercial health plans. In a hypothetical heal...

Vakaramoko Diaby ;

10/26/2023